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ORIGINAL ARTICLE: EARLY PREGNANCYSystematic review and meta-analysis
of genetic association studies in
idiopathic recurrent
spontaneous abortion
Nina Pereza, M.D., Ph.D.,a Sasa Ostojic, M.D., Ph.D.,a Miljenko Kapovic, M.D., Ph.D.,a
and Borut Peterlin, M.D., Ph.D.b
a Department of Biology and Medical Genetics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia; and b Clinical
Institute of Medical Genetics, Department of Gynecology and Obstetrics, University Medical Center, Ljubljana, SloveniaObjectives: 1) To perform the ﬁrst comprehensive systematic review of genetic association studies (GASs) in idiopathic recurrent spon-
taneous abortion (IRSA); 2) to analyze studies according to recurrent spontaneous abortion (RSA) deﬁnition and selection criteria for
patients and control subjects; and 3) to perform meta-analyses for the association of candidate genes with IRSA.
Design: Systematic review and meta-analysis.
Setting: Not applicable.
Patient(s): Couples with IRSA and their spontaneously aborted embryos.
Intervention(s): Summary odds ratios (ORs) were calculated by means of ﬁxed- or random-effects models.
Main Outcome Measure(s): Association of genetic variants with IRSA.
Result(s): The systematic review included 428 case-control studies (1990–2015), which differed substantially regarding RSA
deﬁnition, clinical evaluation of patients, and selection of control subjects. In women, 472 variants in 187 genes were investigated.
Meta-analyses were performed for 36 variants in 16 genes. Association with IRSA deﬁned as three or more spontaneous abortions
(SAs) was detected for 21 variants in genes involved in immune response (IFNG, IL10, KIR2DS2, KIR2DS3, KIR2DS4, MBL, TNF),
coagulation (F2, F5, PAI-1, PROZ), metabolism (GSTT1, MTHFR), and angiogenesis (NOS3, VEGFA). However, ORs were modest
(0.51–2.37), with moderate or weak epidemiologic credibility. Minor differences in summary ORs were detected between IRSA
deﬁned as two or more and as three or more SAs. Male partners were included in 12.1% of studies, and one study included
spontaneously aborted embryos.
Conclusion(s): Candidate gene studies show moderate associations with IRSA. Owing to large differences in RSA deﬁnition and selec-
tion criteria for participants, consensus is needed. Future GASs should include both partners and spontaneously aborted embryos.
Genome-wide association studies and large-scale replications of identiﬁed associations are recommended. (Fertil Steril 2016;-:
-–-. 2016 by American Society for Reproductive Medicine.)
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gists (RCOG) as three or more
consecutive spontaneous abortions
(SAs), whereas the American Society
for Reproductive Medicine (ASRM) de-
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it recommends that only couples with
three or more SAs be included in epide-
miologic studies (1–3). In all three
guidelines, known causes of RSA
include antiphospholipid syndrome1
ORIGINAL ARTICLE: EARLY PREGNANCY(APS) and uterine anatomic anomalies (UAAs) in women, and
chromosome abnormalities (CAs) in either partner. Although
various hypotheses have been tested, causative factors in the
remaining couples (50%) have not been identiﬁed.
The assumption for a genetic predisposition to idiopathic
RSA (IRSA) is based on three observations: 1) siblings of pa-
tients with IRSA exhibit a higher frequency of SA than pop-
ulation control subjects (4–6); 2) the risk of SA increases
with their number (7, 8); and 3) SAs in couples with IRSA
recur at the same gestational age (90% before 12 weeks of
gestation) (9). Numerous genetic factors have been tested,
including DNA methylation, skewed X chromosome
inactivation, chromosome heteromorphisms, sperm DNA
fragmentation, and genetic variation, but none has been
conﬁrmed unanimously as a major risk factor for IRSA.
Genetic association studies (GASs) constitute an especially
large amount of scientiﬁc papers published in this ﬁeld and
were mostly designed as hypothesis-based candidate gene
studies performed in unrelated subjects (10). However, as
our group emphasized previously, comparative analyses are
complicated owing to large differences between studies
regarding the deﬁnition of RSA (minimal number, order,
and gestational age of SAs), diagnostic procedures performed
in patients to exclude the known causes of RSA, and deﬁni-
tion of the control group (11, 12). Furthermore, similarly to
limitations of GASs in other common diseases, results are
often contradictory, not replicated, and/or based on a small
number of participants (13). In addition, certain published
qualitative and qualitative syntheses show limitations. For
example, the criteria for evaluation and inclusion of studies,
particularly meta-analyses, are seldom based on professional
guidelines for the evaluation of couples with RSA, and the
process of study selection is often not conducted in accor-
dance with the proposed criteria (11, 12).
Therefore, to address the current status in the ﬁeld and
contribute to an improved understanding of the role of ge-
netic variation in IRSA, we evaluated the evidence for the as-
sociation of various candidate genes with IRSA in couples and
their offspring through the following speciﬁc objectives: 1) to
perform a comprehensive systematic review of all GASs in the
English language analyzing the association between genetic
variants (polymorphisms and mutations) and IRSA; 2) to
analyze studies according to IRSA deﬁnition and selection
criteria for patients and control subjects; 3) to perform
meta-analyses and compare summary estimates for each ge-
netic variant among three categories of studies: minimum (all
studies with genotype frequencies reported), medium (studies
deﬁning IRSA as two or more SAs), and full (studies deﬁning
IRSA as three or more SAs) criteria, with other rigorous selec-
tion criteria applied for the latter two categories.MATERIALS AND METHODS
Search Strategy
A systematic review of the literature was conducted with the
use of the Pubmed and Scopus electronic databases, which
were searched for publications on the association between ge-
netic variants (polymorphisms and mutations) and IRSA from
January 1, 1990, to January 1, 2015 (25 years). The following2key words were used: ‘‘recurrent pregnancy loss,’’ ‘‘recurrent
miscarriage’’ or ‘‘recurrent spontaneous abortion’’ in combi-
nation with ‘‘gene mutation’’ or ‘‘polymorphism.’’ Because
Pubmed and Scopus are the medical databases with the best
coverage (14, 15), references of retrieved articles were not
additionally hand searched. The search for publications was
performed independently by two authors, and all retrieved
articles were compared to avoid duplication. Any
disagreements were discussed and resolved with consensus.
Systematic review and meta-analyses were performed in
accordance with PRISMA (Preferred Reporting Items of Sys-
tematic Reviews and Meta-analyses) guidelines. Considering
that this study was a systematic review with meta-analyses,
an Institutional Review Board approval was not required.Study Selection
The objective was to identify case-control studies on the asso-
ciation between genetic variants (polymorphisms and muta-
tions) and IRSA with the use of the following exclusion
criteria: non–case-control studies (reviews, case reports,
meta-analyses, cohort studies, book chapters, etc.), studies
performed in patients with RSA of known cause or patients
with IRSA in combination with other disorders (e.g., hydati-
form mole) or patients with IRSA tested for other genetic fac-
tors (copy number variations, X-chromosome inactivation,
epigenetic modiﬁcations, mitochondrial DNA variants,
genome-wide association studies, Y-chromosome microdele-
tions), and studies not related to IRSA (other disorders). Lan-
guage restriction was applied and only reports in the English
language were taken into consideration. Congress abstracts
were included if results did not overlap with those published
in original papers.Meta-analyses
Considering that there are no universal criteria for the deﬁni-
tion of RSA, the criteria for inclusion of studies in meta-
analyses of individual genetic variants were divided into three
categories for comparative analysis of summary estimates:
1. Minimum criteria: Meta-analyses were performed for all
retrieved studies in which genotype frequencies were re-
ported, regardless of RSA deﬁnition, selection criteria for
patients and control subjects, or deviation of genotype fre-
quencies from Hardy-Weinberg equilibrium (HWE) in the
control group.
2. Medium criteria: Meta-analyses were performed for
studies in which IRSA was deﬁned as two or more SAs
(including three or more SAs) and which met the rigorous
inclusion criteria described below.
3. Full criteria: Meta-analyses were performed for studies in
which IRSA was deﬁned as three or more SAs and which
met the rigorous inclusion criteria described below.
The rigorous inclusion criteria for meta-analyses of
studies that appertain to medium and full criteria were: 1)
case-control study in which genotyping was performed in
women and/or men with IRSA and control women and/or
men; 2) diagnosis of IRSA based on ESHRE, RCOG, andVOL.- NO.- /- 2016
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of both partners for exclusion of CAs, ultrasonography and/
or hysteroscopy for exclusion of UAAs) (1–3); 3) control
group deﬁned as women/couples with at least one live birth
and no SA; 4) all genotype frequencies reported; and 5) no
deviation of genotype frequencies from HWE in the control
group. In accordance with previously published large-ﬁeld
synopses in other diseases, comparative analysis for each ge-
netic variant was performed if three or more studies met the
full criteria (16).
We introduced the category of minimum criteria because
we noticed that in some previously published meta-analyses,
all of the retrieved studies in which genotype frequencies were
reported were included in quantitative synthesis regardless of
the quality of studies (11, 12). Our aimwas to objectify the fact
that the results of such analyses might be misleading.
If multiple publications from the same author were
retrieved, only those with the largest number of participants
or where all genotype frequencies were reported were
included in meta-analysis. Genetic variants that are not bial-
lelic or have a complex allelic structure (e.g., HLA, ApoE,
ANXA5, etc.) were considered for meta-analysis if geno-
type/allele/haplotype frequencies were uniformly reported
between studies.Data Extraction
The following data were extracted for each study included in
the systematic review and meta-analysis: authors, year of
publication, population studied, deﬁnition of RSA, number
of patients and control subjects (women, men, spontaneously
aborted conceptuses, children), diagnostic evaluations per-
formed in couples with IRSA (exclusion of APS, CAs, UAAs,
and other possible causes), deﬁnition of control group, and
genetic variants tested. In addition, if a genetic variant was
tested in three or more studies, genotype and allele fre-
quencies were extracted and HWE for genotype frequencies
in the control group was calculated for each study. If a publi-
cation reported genotype frequencies stratiﬁed by the number
of SAs, all numbers were extracted.Statistical Analysis
Conformity of genotype frequencies to HWE in the control
group was tested with the use of the Simple Hardy-
Weinberg Calculator–Court Lab (Washington State University
College of Veterinary Medicine). Deviation from HWE was
determined by a P value < .05.
Meta-analyses were performed with the use of Compre-
hensive Meta-analysis, version 2.2.064 (Biostat). For each
study, individual and summary odds ratios (ORs) and associ-
ated 95% conﬁdence intervals (CIs) were calculated under
dominant and/or recessive genetic models or special models
(e.g.,HLA,KIR, etc.). Associations were conﬁrmed by P values
< .05. Tests for statistical heterogeneity were performed for
each meta-analysis with the use of Cochran Q test. If the P
value was< .05, aﬁxed-effects model was applied. Otherwise,
random-effects model was applied. Because there was no
severe statistical heterogeneity in meta-analyses performedVOL.- NO.- /- 2016under full criteria, sensitivity analysis was not conducted.
Publication bias was evaluated under full criteria with the
use of the funnel plot and Egger regression test for associa-
tions with P values < .05.Assessment of Cumulative Epidemiologic
Evidence
Cumulative epidemiologic evidence for genetic variants un-
der full criteria was assessed with the use of the Venice criteria
(17). Epidemiologic credibility for each meta-analysis was
graded on three levels: amount of evidence, extent of replica-
tion, and protection from bias. The amount of evidence was
evaluated by the total number of minor allele copies (MAC)
in case and control subjects for each variant (grade A: total
number of MAC >1,000; grade B: total number of MAC ¼
100–1,000; grade C: total number of MAC <100). Extent of
replication was evaluated by the amount of statistical hetero-
geneity as measured by means of I2 (grade A: I2<25%; grade
B: I2 ¼ 25%–50%; grade C: I2 >50%). Considering that we
aimed to select well designed studies for inclusion in the
meta-analysis under full criteria (e.g., similar phenotype deﬁ-
nition, appropriate genotyping methods, no deviations from
HWE), protection from bias was evaluated by the magnitude
of association, minor differences in IRSA deﬁnition, and pop-
ulation differences. Grade A was assigned when the summary
ORwas>1.15 with uniform IRSA deﬁnitions and similar pop-
ulations involved in analysis; grade B was assigned when the
summary OR was>1.15 but minor differences in IRSA deﬁni-
tion were present (e.g., consecutive/nonconsecutive SAs) or
different populations were involved in analysis; grade C
was given when the summary OR was <1.15 or if there was
presence of publication bias. Final categories for the credi-
bility of cumulative epidemiologic evidence were assigned
as suggested by Ioannidis et al. (17).
RESULTS
A total of 428 case-control studies in the English language on the
association between genetic variants and IRSA were identiﬁed
through the comprehensive literature searching (Supplemental
Fig. 1; Supplemental Figs. 1 and 2, Supplemental Tables 1–6,
and Supplemental Appendix 1 are available online at
www.fertstert.org). The distribution of these studies in the past
25 years is shown in Supplemental Figure 2, and the numbers
of participants tested are presented in Supplemental Table 1.
Because of the comprehensiveness of the present systematic
review, we present only descriptive data in the tables, and the
complete literature list is available in Supplemental Appendix 1.Deﬁnition of Recurrent Spontaneous Abortion
Different deﬁnitions of RSA in retrieved studies are presented
in Table 1. The deﬁnition was evaluated according to the
following criteria: number, order, and gestation period of
SAs, whether the SAs occurred with the same partner, number
of live born children, and other inclusion criteria. We detected
huge differences among the studies, with a total of 130
different deﬁnitions: 160 studies deﬁned RSA as two or
more SAs (37.4%), 227 studies deﬁned RSA as three or more3
TABLE 1
Deﬁnitions of recurrent spontaneous abortion in retrieved studies in descending order.
Deﬁnition SAs, n
Order
SAs with
same partner Gestation period
Live birth
Other Studies, nConsecutive Nonconsecutive Primary Secondary
1. R2 þ 33
2. R2 22
3. R2 þ <20 WOG 9
4. R2 <20 WOG 8
5. R2 þ þ þ 7
6. R2 þ þ 7
7. R2 þ <12 WOG 7
8. R2 þ þ 6
9. R2 þ 6
10. R2 þ þ þ SA and SB 5
11. R2 1st trimester 4
12. R2 þ <25 WOG 3
13. R2 þ <24 WOG þ 3
14. R2 þ <12 WOG þ 3
15. R2 þ þ 2
16. R2 SA and SB 2
17. R2 þ <22 WOG 2
18. R2 þ <20 WOG þ 2
19. R2 þ þ 5–12 WOG þ 2
20. R2 þ 1st trimester 2
21. R2 During pregnancy 2
22. R2 þ 1
23. R2 þ þ Clinical SA 1
24. R2 þ <25 WOG þ 1
25. R2 <20 WOG þ 1
26. R2 <20 WOG þ þ 1
27. R2 þ <20 WOG þ þ 1
28. R2 þ <20 WOG <35 YOA 1
29. R2 þ þ <20 WOG 1
30. R2 þ þ <20 WOG 1
31. R2 þ þ <20 WOG þ 1
32. R2 <17 WOG 1
33. R2 þ þ <17 WOG 1
34. R2 þ <17 WOG 1
35. R2 þ þ <15 WOG 1
36. R2 þ þ <14 WOG 1
37. R2 þ <14 WOG þ 1
38. R2 <13 WOG þ þ Clinical SA 1
39. R2 þ þ 8–12 WOG 1
40. R2 þ 6–10 WOG 1
41. R2 þ 1st trimester þ 1
42. R2 þ During pregnancy 1
43. R2 þ Early pregnancy þ 1
44. R2 þ Max 1 live birth 1
45. R3 25
46. R3 þ 20
47. R3 þ 16
48. R3 þ þ <20 WOG 14
49. R3 þ <20 WOG 11
50. R3 þ <20 WOG 9
51. R3 1st trimester þ 8
52. R3 þ Early pregnancy þ þ 8
53. R3 1st trimester 7
54. R3 þ <20 WOG þ 5
55. R3 þ þ 1st trimester þ þ 5
56. R3 þ þ 4
57. R3 þ þ þ 4
58. R3 þ þ <24 WOG 4
59. R3 <20 WOG 4
60. R3 þ þ <20 WOG þ 4
61. R3 þ þ 1st trimester 4
62. R3 þ 3
63. R3 þ þ 3
64. R3 þ 5–30 WOG 3
65. R3 <24 WOG 3
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TABLE 1
Continued.
Deﬁnition SAs, n
Order
SAs with
same partner Gestation period
Live birth
Other Studies, nConsecutive Nonconsecutive Primary Secondary
66. R3 þ 5–21 WOG 3
67. R3 þ <13 WOG 2nd trimester, IUFD 3
68. R3 <12 WOG þ 3
69. R3 þ þ <12 WOG 3
70. R3 þ 1st trimester 3
71. R3 þ þ 2
72. R3 þ þ þ 2
73. R3 þ þ <30 WOG 2
74. R3 þ <24 WOG 2
75. R3 þ <22 WOG þ þ 2
76. R3 <20 WOG Max 1 livebirth 2
77. R3 <12 WOG 2
78. R3 þ <10 WOG 2
79. R3 þ 1st trimester 2
80. R3 þ 1st trimester þ þ 2
81. R3 1st or 2nd trimester 2
82. R3 þ þ 1
83. R3 þ þ þ þ 1
84. R3 <30 WOG 1
85. R3 þ <30 WOG þ þ 1
86. R3 <28 WOG þ þ 1
87. R3 <28 WOG þ þ þ SB 1
88. R3 þ <28 WOG þ þ 1
89. R3 þ <28 WOG þ þ þ SB 1
90. R3 þ <25 WOG 1
91. R3 <23 WOG 1
92. R3 þ <23 WOG 1
93. R3 þ <22 WOG 1
94. R3 þ <22 WOG 1
95. R3 þ 5–21 WOG þ þ 1
96. R3 þ þ <20 WOG þ þ 1
97. R3 þ þ 6–20 WOG 1
98. R3 10–20 WOG 1
99. R3 þ þ <14 WOG 1
100. R3 þ 5–14 WOG Clinical SA 1
101. R3 þ 6–13 WOG 1
102. R3 þ <12 WOG 1
103. R3 þ þ <12 WOG þ þ 1
104. R3 þ þ 1st trimester þ 1
105. R3 þ 1st trimester þ þ 1
106. R3 any trimester 1
107. R3 þ þ 1st or 2nd trimester 1
108. 1–5 1
109. R4 1
110. R5 1
111. ND 12
Special criteria
112. R2 SAs in 1st trimester orR1 late SA 3
113. R2 consecutive SAs or 3–6
nonconsecutive early SAs
3
114. R2 consecutive SAs or 3–6
nonconsecutive SAs (8–12 WOG)
2
115. 2 consecutive SAs orR3
nonconsecutive SAs (8–12 WOG)
2
116. R3 consecutive SAs <12 WOG or
R1 late miscarriage (>12 WOG)
2
117. R2 SAs <24 WOG orR1 IUFD >24
WOG and max. 1 livebirth
1
118. R2 SAs <12 WOG or 1 SA >12
WOG
1
119. R2 SAs <10 WOG orR1 mid-
trimester or 3rd trimester IUFD
and/or IUGR
1
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TABLE 1
Continued.
Special criteria
120. R2 consecutive SAsR21 WOG with
the same partner orR1 SA >21
WOG
1
121. R2 consecutive SAs in 1st trimester
orR3 SAs in 1st trimester (R16
WOG)
1
122. R3 SAs in 1st trimester orR2 SAs in
2nd or 3rd trimester
1
123. R3 SAs in any trimester or 1 SA in
2nd or 3rd trimester
1
124. R3 consecutive SAs <12 WOG and
no late fetal loss or atR1 late
fetal loss (>12 WOG)
1
125. R3 consecutive SAs in 1st trimester
or 2 consecutive SAs in 2nd
trimester orR1 IUFD
1
126. R3 consecutive SAs orR2
consecutive SAs followed by
severe IUGR or placenta
abruption, primary/secondary
1
127. R3 consecutive primary SAs <10
WOG or 2 consecutive SAsR10
WOG
1
128. R3 consecutive primary SAs <12
WOG or 2 SAs >12 WOG
1
129. R3 consecutive primary/secondary
SAs <12 WOG andR2 late SAs
(>12 WOG)
1
130. unclear:R2 SAs <20 WOG (later in
textR3 primary SAs)
1
Note: IUFD ¼ intrauterine fetal death; IUGR ¼ intrauterine growth restriction; ND ¼ not deﬁned; SA ¼ spontaneous abortion; SB ¼ stillbirth; WOG ¼ weeks of gestation; YOA ¼ years of age.
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(6.8%), and no deﬁnition was indicated in 12 studies (2.8%).
Within these categories, studies also differed to a great extent
regarding other criteria.TABLE 2
Exclusion of known causes of recurrent spontaneous abortion in
retrieved studies.
Not excludedExclusion of Known Causes of Recurrent
Spontaneous Abortion
All three known causes of RSA (APS, CA, UAA) were excluded
in 220 (51.4%) studies (Table 2). Other diagnostic procedures
performed in patients with IRSA, mostly women, were exten-
sive and mainly included testing for hereditary and acquired
thrombophilias and endocrine, autoimmune, and metabolic
disorders.APS CA UAA if positive Studies, n
þ þ þ 220
þ þ 103
ND ND ND 37
þ 16
þ (APS, CA, UAA) 15
þ 15
þ þ 9Selection Criteria for the Control Group
Selection criteria for the control group are presented in
Table 3. We found 23 different combinations of inclusion
criteria regarding the number of SAs and live born children
and whether there were no other pregnancy complications.þ (APS) 5
þ (CA) 3
þ (APS, CA) 2
þ 3
Note: APS ¼ antiphospholipid syndrome; CA ¼ chromosome abnormality; ND ¼ not
deﬁned; UAA ¼ uterine anatomic anomaly.
Pereza. Genetic associations with IRSA. Fertil Steril 2016.Genetic Variants Investigated in Women
In women with IRSA, 472 variants in 187 genes were investi-
gated, involved mostly in immune response, coagulation,
metabolism, angiogenesis, endocrine system, and regulation6of vascular function (Supplemental Table 2). In addition, in
eight genes the variants tested were not speciﬁed, and the re-
sults of sequencing for 12 genes were too extensive to be dis-
played individually or the variants identiﬁed were not
speciﬁed. A total of 305 variants (64.6%) in 142 genes and
four unspeciﬁed variants in four genes were tested in only
one study. A further 131 variants (27.8%) in 79 genes wereVOL.- NO.- /- 2016
TABLE 3
Selection criteria for the control group of women/couples in retrieved
studies.
SA, n Live birth, n
No other pregnancy
complication Studies, n
0 R2 104
0 R1 95
ND ND 42
0 R1 þ 41
0 R2 þ 37
ND R2 19
0 Multipara 17
ND R1 17
0 ND 15
ND Multipara 9
0 Multipara þ 6
ND ND þ 5
0 ND þ 4
%1 R2 4
ND R1 þ 3
%1 R1 2
ND R2 þ 2
ND Multipara þ 1
Special criteria
Women with venous
thromboembolism,
uteroplacental dysfunction, or
atherothrombotic disease and
women without SA, venous
thromboembolism,
uteroplacental dysfunction, or
atherothrombotic disease
1
R1 normal pregnancies resulting in
a full-term (>37 wk) live birth,
with appropriate weight for
gestational age, excluding
women with >2 SAs or any late
loss and non–English-speaking
women
1
Nonpregnant women without
obstetrical complications or SA,
including women with and
without live births
1
R1 successful pregnancies and
without RSA or infertility
1
Parous women without RSA or
thrombosis
1
Note: ND ¼ not deﬁned; RSA ¼ recurrent spontaneous abortion; SA ¼ spontaneous
abortion.
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formed because no more than two studies met the full criteria
(Supplemental Table 3). Finally, 150 meta-analyses were per-
formed for 36 variants (7.6%) in 16 genes.
Full criteria. Association with IRSA deﬁned as three or more
SAs was detected for 21 variants in 13 genes (Table 4;
Supplemental Tables 4 and 5). Overall, the genetic variants
showed modest effects on IRSA, with ORs ranging from
0.51 to 2.37. None of the associations reached strong epidemi-
ologic credibility. Publication bias was detected for the
MTHFR C677T single-nucleotide polymorphism under a
recessive genetic model (t ¼ 2.6; df ¼ 10; P¼ .028).
Comparison of summary estimates between categories of
criteria. Regardless of the category of criteria, the ORs thatVOL.- NO.- /- 2016reached statistical signiﬁcance were modest (Table 4;
Supplemental Table 4). Nevertheless, several differences
emerged when comparing the three categories.
The differences between meta-analyses performed under
minimum and full criteria are most obvious regarding
statistical heterogeneity, which reached signiﬁcance in 22
meta-analyses under minimum criteria, but was lost in 11
meta-analyses under full criteria. This was especially notice-
able for meta-analyses that included the largest number of
studies (e.g., F2 G20210A, F5 Leiden,MTHFR C677T,MTHFR
A1298C). Association with IRSAwas detected forGSTT1 null/
present variant under full criteria but not under minimum
criteria. Conversely, compared with minimum criteria, associ-
ation with RSA was lost for eight variants under full criteria
(GSTM1 null/present, HLA-G I/D 14-bp, IL10 1082 G/A,
MTHFR A1298C, NOS3 þ894 G/T, PAI-1 4G/5G, TNF
308 G/A, VEGFA þ936 C/T).
Comparison between medium and full criteria was
possible for 18 meta-analyses. Statistical heterogeneity and
ORs were similar between these categories. However, under
full criteria, GSST1 null/present, MTHFR C677T, and PAI-1
4G/5G variants became associated with IRSA, whereas asso-
ciation was lost for IFNG þ874 A/T variant.Genetic Variants Investigated in Men and
Offspring
Genetic variants investigated in male partners of IRSA
women are presented in Supplemental Table 6. A total of 73
variants in 42 genes were investigated in 52/428 studies
(12.1%). In addition, tested variants were not speciﬁed for
ﬁve genes, and the results of sequencing of three genes
were too extensive or the variants identiﬁed were not speci-
ﬁed. Meta-analyses were not performed.
Live born children of couples with IRSA were tested for
C4A, C4B, CFB, CGB5, HLA (A, B, C, DRB, DQA, DQB,
DPA, DPB), and LTA gene variants in four studies, whereas
only theMTHFR A1298C variant was tested in spontaneously
aborted embryos in one study.
DISCUSSION
We performed the ﬁrst comprehensive systematic review and
meta-analysis of all GASs in IRSA published in the past
25 years (1990–2015) to provide quantitative summary esti-
mates of the effect of genetic variants on the odds for IRSA.
We evaluated 428 case-control studies, including the largest
number of IRSA couples and control subjects in qualitative
and quantitative analyses up to now.Characteristics of Retrieved Studies
The most important quality determinant of any meta-analysis
is the inclusion of well designed original studies with identical
or nearly identical selection criteria for patients and control
subjects, which minimalizes heterogeneity and biased sum-
mary estimates. Although initially our goal was solely to
compare the summary estimates among different categories
of studies, our systematic review revealed many other issues
that need to be addressed in future studies. The most7
TABLE 4
Results of meta-analyses for gene variants showing association with idiopathic recurrent spontaneous abortion in women under full criteria.
Gene variation Minimum criteria Medium criteria Full criteria
Gene Variant Studies, n
Participants,
n (WP:WC) Genetic model
OR (95% CI);
P value
I2;
P value Studies, n
Participants,
n (WP:WC)
OR (95% CI);
P value
I2;
P value Studies, n
Participants,
n (WP:WC)
OR (95% CI);
P value
I2;
P value Venice criteriaa
F2 G20210Ab 71/54c 6,790:6,327 Dominant
AAþAG vs. GG
1.75 (1.31–2.35); .000 33.4; .013 25 3,880:3,718 1.77 (1.29–2.42); .000 11.9; .299 13 2,257:1,993 1.73 (1.10–2.73); .018 0.0; .653 CAB (weak)
F5 Leidenb 91/72c 10,286:9,132 Dominant
AAþAG vs. GG
2.19 (1.76–2.71); .000 58.2; .000 29 5,108:4,000 1.61 (1.32–1.97); .000 33.2; .053 14 1,585:1,712 1.74 (1.26–2.39); .001 3.3; .411 BAB (moderate)
GSTT1 null/present 7 1,016:1,026 Null vs. present
gene
1.26 (0.88–1.80); .201 62.0; .015 6 901:866 1.35 (0.90–2.04); .148 64.6; .015 4 593:644 1.65 (1.22–2.23); .001 59.9; .058 BCB (weak)
IFNG þ874 A/T 7 683:787 Dominant
TTþAT vs. AA
1.27 (1.02–1.59); .036 32.9; .176 4 342:491 1.47 (1.10–1.96); .009 19.8; .291 3 281:416 1.61 (1.18–2.21); .003 0.0; .425 BAB (moderate)
IL10 1082 G/A 13/11c 1,724:1,739 Recessive
GG vs. AGþAA
1.54 (1.12–2.12); .009 55.7; .012 3 549:680 1.95 (1.35–2.80); .000 0.0; 1.000 3 549:680 1.95 (1.35–2.80); .000 0.0; 1.000 BAB (moderate)
KIR KIR2DS2 5/4 345:388 1.58 (1.16–2.16); .004 0.0; .518 3 272:320 1.68 (1.20–2.37); .003 0.0; .451 3 272:320 1.68 (1.20–2.37); .003 0.0; .451 BAB (moderate)
KIR2DS3 5/4 345:388 1.70 (1.24–2.33); .001 0.0; .547 3 272:320 1.83 (1.28–2.61); .001 0.0; .540 3 272:320 1.83 (1.28–2.61); .001 0.0; .540 BAB (moderate)
KIR2DS4 5/4 345:388 0.54 (0.38–0.75); .000 47.0; .129 3 272:320 0.51 (0.36–0.72); .000 36.8; .205 3 272:320 0.51 (0.36–0.72); .000 36.8; .205 BBC (weak)
MBL 550 H/L
221 X/Y
codon 52
codon 54
codon 57
4/3c 333:408 Low vs.
intermediate þ
highd
1.92 (1.12–3.27); .017 55.5; .106 3 333:408 1.92 (1.12–3.27); .017 55.5; .106 3 282:408 1.96 (1.14–3.38); .015 53.9; .114 BCB (weak)
MTHFR C677T 79/56c 7,097:5,911 Dominant
TTþCT vs. CC
1.26 (1.08–1.48); .004 73.0; .000 27 3,413:2,912 1.22 (1.00–1.48); .052 66.8; .000 13 1,685:1,491 1.31 (1.13–1.53); .000 28.8; .155 ABB (moderate)
79/61c 7,354:6,517 Recessive
TT vs. CTþCC
1.50 (1.25–1.79); .000 47.2; .000 1.48 (1.14–1.91); .003 43.1; .011 1.67 (1.28–2.19); .000 0.0; .568 AAC (weak)
A1298C 29/20c 2,973:2,618 Recessive
CC vs. ACþAA
1.86 (1.31–2.64); .000 46.6; .012 9 1,151:1,277 1.53 (1.09–2.14); .013 36.2; .128 6 838:952 1.55 (1.08–2.23); .017 53.4; .057 ACB (weak)
NOS3 þ894 G/T 10 1,984:1,612 Dominant
TTþGT vs. GG
1.38 (1.00–1.91); .047 76.0; .000 6 1,108:1,107 1.54 (1.03–2.30); .034 77.0; .001 5 963:972 1.78 (1.25–2.55); .001 64.6; .023 BCB (weak)
PROZ 79 G/A 4 420:433 Recessive
AA vs. AGþGG
2.37 (1.01–5.56); .047 0.0; .851 3 380:403 2.37 (1.01–5.56); .047 0.0; .851 3 380:403 2.37 (1.01–5.56); .047 0.0; .851 BAB (moderate)
SERPINE1 4G/5G 28/21c 3,722:2,948 Dominant
4G4Gþ4G5G vs.
G5G
1.47 (1.13–1.90); .004 79.1; .000 9 1,538:1,507 1.35 (0.98–1.86); .069 71.2; .001 4 673:903 1.71 (1.09–2.67); .019 71.1; .016 ACB (weak)
TNF 308 G/A 18/15c 2,111:2,294 Dominant
AAþAG vs. GG
1.25 (1.07–1.46); .006 30.7; .124 4 628:868 1.47 (1.15–1.89); .002 52.2; .099 4 628:868 1.47 (1.15–1.89); .002 52.2; .099 BCB (weak)
VEGFA 1154 G/A 12/11c 1,929:2,139 Recessive
AA vs. AGþGG
1.71 (1.34–2.18); .000 42.0; .069 4 808:1,024 1.53 (1.10–2.15); .013 35.2; .201 3 693:854 1.61 (1.13–2.28); .008 45.5; .159 BBB (moderate)
634 G/C 7 1,065:1,469 Recessive
CC vs. CGþGG
1.41 (1.14–1.74); .001 0.0; .837 4 673:940 1.55 (1.19–2.02); .001 0.0; .840 4 673:940 1.55 (1.19–2.02); .001 0.0; .840 AAB (moderate)
Note: CI ¼ conﬁdence interval; OR ¼ odds ratio; WP ¼ women patients; WC ¼ women control subjects.
a The ﬁrst letter represents the amount of evidence, the second letter the extent of replication, and the third letter protection from bias.
b Hardy-Weinberg equilibrium was not calculated, because the mutation is dominant and frequencies of mutated homozygotes and heterozygotes are often shown together.
c The number after the slash indicates the number of studies in which genotype frequencies were presented and for which meta-analyses were performed.
d Hardy-Weinberg equilibrium was not calculated, because genotypes were grouped into three categories.
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Fertility and Sterility®prominent of these is the selection of patients according to
deﬁnition of RSA. Despite the existence of professional guide-
lines, we found an astonishing 130 different combinations of
the minimum number, order, and gestational age of SAs,
number of live born children, and other criteria necessary
for the deﬁnition of RSA. The combinations of criteria for in-
clusion in the control group were also numerous; however,
there are no recommendations for the deﬁnition of the control
group for studies of patients with IRSA. Finally, the manda-
tory diagnostic procedures for couples with RSA were per-
formed in only one-half of the retrieved studies. At the
same time, women/couples were tested for a variety of other
disorders even in the absence of clinical indications.
The vast number of different selection criteria for patients
with IRSA and their control groups points to huge discrep-
ancies between studies, making comparison difﬁcult and call-
ing for an urgent consensus on RSA. These difﬁculties were
ﬁnally most strongly indicated by the small number of studies
included in meta-analyses under full criteria.
Wewould also like to emphasize that in some publications,
paragraphs describing the selection of participants were writ-
ten in such an intricate manner that repeated readings were
required. If certain data (e.g., genotype frequencies, selection
criteria for patients and control subjects, etc.) was missing or
was not presented clearly in the original paper, authors were
not contacted, because according to STREGA (Strengthening
the Reporting of Genetic Association Studies) recommenda-
tions, this information should be reported (18). The lack of
such data should prompt future researchers to comply with
STREGA recommendations to enhance the transparency of re-
porting and allow future cumulative synthesis of results.Association of Genetic Variants with Idiopathic
Recurrent Spontaneous Abortion in Women
Out of 472 identiﬁed variants, the majority (64.6%) were
tested in only one study and an additional 27.8% of variants
could not be included in meta-analyses, precluding us from
making conclusions on their associations with IRSA. Associ-
ation with IRSA deﬁned as three or more SAs was detected for
21 variants in 13 genes. Considering their function, these
genes are involved in immune response (IFNG, IL10,
KIR2DS2, KIR2DS3, KIR2DS4, MBL, TNF), coagulation (F2,
F5, PAI-1, PROZ), metabolism (GSTT1, MTHFR), and angio-
genesis (NOS3, VEGFA). However, ORs of all associations
were modest. In addition, although these systems have been
associated with IRSA in theory, the pathophysiologic mecha-
nisms of how speciﬁc genetic variants might contribute to SA
are largely unexplored.
Considering the ongoing debate on the minimum number
of SAs necessary for the diagnosis of RSA (two or more vs.
three or more SAs), we performed comparative analysis for
each genetic variant included in meta-analysis to evaluate
whether there is a difference in summary estimates between
women with two or more versus three or more SAs. No major
differences in statistical heterogeneity and ORs were
observed, although under full criteria, three variants became
associated with IRSA, whereas association was lost for one
variant.VOL.- NO.- /- 2016On the other hand, the differences betweenmeta-analyses
performed under minimum and full criteria were evident and
multiple. The most obvious difference concerned the associa-
tion with IRSA, the statistical signiﬁcance of which changed
for nine genetic variants under full criteria. Another obvious
difference concerned the decline in statistical heterogeneity
under full criteria, which is the consequence of reduction in
selection bias. Therefore, only studies with well deﬁned pa-
tient and control groups should be included in quantitative
synthesis, because the results of studies without transparent
selection criteria for participants might be false positive or
false negative.Association of Genetic Variants with Idiopathic
Recurrent Spontaneous Abortion in Male Partners
and Offspring
Our results show that male partners of women with IRSA are
largely underrepresented in GASs (12.1% of studies). Unfortu-
nately, the concept that unsuccessful pregnancy is a female
issue is still a prevailing one, which we can also conﬁrm
from the repeated inquiries of reviewers on why we chose to
include male partners in our studies. The association of stud-
ied genetic variants with IRSA in male partners could not be
estimated, owing to the low number of studies that met the
full criteria for meta-analysis. Furthermore, we found only
one study in which spontaneously aborted embryos were
investigated. The discouraging statistics on the involvement
of male partners and spontaneously aborted embryos in
GAS emphasizes the need for a necessary shift in thinking
on pregnancy in general.Study Limitations and Strengths
The limitations of our study originatemostly from the original
studies. Owing to different diagnostic criteria, meta-analyses
under full criteria were performed on a small number of
studies. Subgroup analyses in different populations were
therefore not performed, although for meta-analyses in which
the largest number of studies were included, populations were
mostly white. In addition, owing to the large number of RSA
deﬁnitions in original studies, we deﬁned RSA only as two or
more and three or more SAs under medium and full criteria
without taking into consideration the order or gestation
period of SAs.
There are also several strengths to this study. The search
for literature was comprehensive and systematic. To draw
attention to the importance of good design of original studies,
quantitative analyses were performed under three categories
of criteria (minimum, medium, and full). Regardless of the
presence of statistical heterogeneity in meta-analyses under
full criteria, which might reﬂect population differences, selec-
tion bias was reduced to a minimum. Homogeneity of the
study population was increased by applying rigorous criteria
for study selection, which were based on ESHRE, RCOG, and
ASRM guidelines. Finally, we objectively present for the ﬁrst
time the differences between studies regarding RSA deﬁni-
tion, exclusion of known causes of RSA, and selection criteria
for the control group.9
ORIGINAL ARTICLE: EARLY PREGNANCYFuture Research
The present results represent the current situation in the ﬁeld.
We strongly recommend the development of guidelines for
GASs in IRSA. Such guidelines already exist for preterm birth
(19). Original studies should indicate the order, number, and
gestation period of SAs, number of live born children, and
whether the SAs occurred with the same partner. In addition,
in studies in which RSA is deﬁned as two or more SAs, results
for women/couples with three or more SAs should be pre-
sented separately. Likewise, we recommend the development
of universal professional guidelines for evaluation and treat-
ment of RSA. Researchers should also comply with STREGA
recommendations.
Future GASs should focus on the most promising associ-
ations and hypothesis-free studies. We identiﬁed only two
genome-wide association studies in our search, but with
different risk loci (6, 20). Repetition of well designed single-
study research in which associations of genetic variants
with IRSA were detected is also advised. Finally, expression
studies are needed to clarify the functional role of genetic var-
iants in IRSA.
CONCLUSION
Candidate gene studies show moderate associations with
IRSA in women. Due to large differences between studies
regarding the deﬁnition of RSA and selection criteria for
participants, consensus is urgently needed. Future GAS
should include both partners with IRSA and spontaneously
aborted embryos. Genome-wide association studies and
large-scale replications of identiﬁed associations should be
performed.
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